CDT EQUITY INC (CDT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put CDT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is highly volatile — it swings about 8% on a typical day and fell roughly 100% in its worst 12-month stretch.
View RiskCDT is an unprofitable healthcare name with unsteady management. The company has no earnings history on record. It recently approved a 1-for-25 reverse stock split. This move aims to maintain Nasdaq listing compliance. The desk lacks valuation data to compare multiples. It also lacks data to measure priced-in expectations. Recession fears could hit this cyclical name harder. The sector backdrop is currently supportive. Peer multiples imply a price about 12% above where it trades. This read is provisional. Our standing thesis remains intact.
Trailing returns as of 2026-11-04. CDT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare CDT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CDT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CDT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain Nasdaq listing compliance via reverse stock split
Reverse stock split aids Nasdaq compliance efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Threatens: Strengthen balance sheet by reducing legacy debt and simplifying capital struct…
Issuing convertible notes may complicate balance sheet strengthening.

Advances: Execute strategic M&A and licensing to create shareholder value
Partnership aligns with strategic M&A and licensing goals.
